Björn Rüter

2.1k total citations
29 papers, 1.4k citations indexed

About

Björn Rüter is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Björn Rüter has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 13 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Björn Rüter's work include Acute Myeloid Leukemia Research (24 papers), Epigenetics and DNA Methylation (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Björn Rüter is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Epigenetics and DNA Methylation (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Björn Rüter collaborates with scholars based in Germany, Netherlands and United States. Björn Rüter's co-authors include Michael Lübbert, Pierre W. Wijermans, Rainer Claus, Arnold Ganser, Uwe Platzbecker, P. Wijermans, Ulrich Germing, Jürgen Finke, Anne Hagemeijer and Hartmut Bertz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Björn Rüter

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Björn Rüter Germany	12	1.2k	647	342	245	163	29	1.4k
Sylvain Thépot France	19	1.0k 0.9×	542 0.8×	408 1.2×	214 0.9×	200 1.2×	81	1.3k
Richard E. Helmer United States	6	851 0.7×	694 1.1×	269 0.8×	188 0.8×	140 0.9×	9	1.3k
Inge Høgh Dufva Denmark	12	843 0.7×	402 0.6×	309 0.9×	265 1.1×	264 1.6×	22	1.1k
EH Estey United States	18	834 0.7×	370 0.6×	533 1.6×	385 1.6×	444 2.7×	25	1.4k
Elisabeth T Korthof Netherlands	13	605 0.5×	383 0.6×	143 0.4×	260 1.1×	245 1.5×	18	1.1k
JR Testa United States	15	1.0k 0.9×	541 0.8×	238 0.7×	414 1.7×	104 0.6×	27	1.3k
Lisa Pleyer Austria	18	435 0.4×	369 0.6×	309 0.9×	115 0.5×	248 1.5×	53	947
Eva Hellström-Lindberg Sweden	12	761 0.6×	221 0.3×	320 0.9×	68 0.3×	225 1.4×	22	987
CM Rubin United States	15	847 0.7×	432 0.7×	228 0.7×	376 1.5×	97 0.6×	20	1.0k
ER van Wering Netherlands	17	1.0k 0.8×	347 0.5×	278 0.8×	1.2k 5.0×	264 1.6×	17	1.7k

Countries citing papers authored by Björn Rüter

Since Specialization

Citations

This map shows the geographic impact of Björn Rüter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Björn Rüter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Björn Rüter more than expected).

Fields of papers citing papers by Björn Rüter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Björn Rüter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Björn Rüter. The network helps show where Björn Rüter may publish in the future.

Co-authorship network of co-authors of Björn Rüter

This figure shows the co-authorship network connecting the top 25 collaborators of Björn Rüter. A scholar is included among the top collaborators of Björn Rüter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Björn Rüter. Björn Rüter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Komrokji, Rami S., Hetty E. Carraway, Ulrich Germing, et al.. (2022). A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome. Haematologica. 107(11). 2742–2747. 6 indexed citations

Vasu, Sumithira, Jessica K. Altman, Geoffrey L. Uy, et al.. (2021). A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica. 107(3). 770–773. 7 indexed citations

Becker, Heiko, Dietmar Pfeifer, Gabriele Ihorst, et al.. (2020). Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Annals of Hematology. 99(7). 1551–1560. 11 indexed citations

Becker, Heiko, Stefan Suciu, Björn Rüter, et al.. (2015). Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Annals of Hematology. 94(12). 2003–2013. 16 indexed citations

Lübbert, Michael, Björn Rüter, Rainer Claus, et al.. (2011). A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 97(3). 393–401. 172 indexed citations

Lübbert, Michael, Stefan Suciu, Liliana Baila, et al.. (2011). Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology. 29(15). 1987–1996. 403 indexed citations

Manegold, Christian, Johan Vansteenkiste, Felipe Cardenal, et al.. (2009). A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Journal of Thoracic Oncology. 4(9). 1 indexed citations

Lübbert, Michael, Hartmut Bertz, Björn Rüter, et al.. (2009). Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplantation. 44(9). 585–588. 70 indexed citations

Manegold, C., Johan Vansteenkiste, F. Cardenal, et al.. (2009). Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients (pts) with stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8014–8014. 5 indexed citations

10.

Lübbert, Michael, et al.. (2008). Efficacy of a 3-Day, Low-Dose Treatment with 5-Azacytidine Followed by Donor Lymphocyte Infusions (DLI ) in Older AML/MDS Patients Relapsed after Allografting.. Blood. 112(11). 3248–3248. 1 indexed citations

11.

Wijermans, P., et al.. (2007). Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia Research. 32(4). 587–591. 91 indexed citations

12.

Deschler-Baier, Barbara, Gabriele Ihorst, John D. Hummel, et al.. (2007). P.11 Multidimensional geriatric assessment in elderly patients with MDS/AML. Critical Reviews in Oncology/Hematology. 64. S38–S38. 1 indexed citations

13.

Lübbert, Michael, Björn Rüter, Rainer Claus, et al.. (2007). Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.. Blood. 110(11). 300–300. 19 indexed citations

14.

Valent, Peter, Hans‐Peter Horny, John M. Bennett, et al.. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia Research. 31(6). 727–736. 355 indexed citations

15.

Rüter, Björn, et al.. (2006). DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML. Current Pharmaceutical Biotechnology. 7(5). 315–321. 39 indexed citations

16.

Rüter, Björn, Pierre W. Wijermans, & Michael Lübbert. (2006). Superiority of prolonged low‐dose azanucleoside administration?. Cancer. 106(8). 1744–1750. 50 indexed citations

17.

Lübbert, Michael, Hartmut Bertz, Björn Rüter, Roland Mertelsmann, & Jürgen Finke. (2006). Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients.. Blood. 108(11). 5257–5257. 8 indexed citations

18.

Rüter, Björn, Pierre W. Wijermans, & Michael Lübbert. (2004). DNA Methylation as a Therapeutic Target in Hematologic Disorders: Recent Results in Older Patients with Myelodysplasia and Acute Myeloid Leukemia. International Journal of Hematology. 80(2). 128–135. 53 indexed citations

19.

Lübbert, Michael, Pierre W. Wijermans, & Björn Rüter. (2004). Re-Treatment with Low-Dose 5-Aza-2′-Deoxycytidine (Decitabine) Results in Second Remissions of Previously Responsive MDS Patients.. Blood. 104(11). 1447–1447. 7 indexed citations

20.

Rüter, Björn, et al.. (2000). Brief communication. Outcrossing rates and relatedness estimates in pecan Carya illinoinensis) populations. Journal of Heredity. 91(1). 72–75. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact